Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Q4 2021 Earnings Presentation
18 slides from Getinge Ab Class B's earnings presentation, Jan 28, 2022
Slide 1: Healthy order growth, improved margins and strong Cash Flow
Healthy order growth, improved margins and strong Cash Flow Getinge Q4 2021 Mattias Perjos, CEO Lars Sandström, CFO
Slide 2: Key takeaways – a strong quarter from a financial perspective
Key takeaways – a strong quarter from a financial perspective Q4 2021 • Healthy organic order growth • Improved margins • Strong Free Cash Flow • Solid financial position • Proposed dividend/share, SEK: 4.00 (3.00) 53.2 27,049 19.3 25,000 50 15 0 0 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3
Slide 3: Key activities and events
Key activities and events Q4 2021 Strengthening the offering further BetaBag® capacity increase • Acquisition of Talis Clinical, a US-based leading • Production of DPTE BetaBag® in innovator of High Acuity cloud-based software Merrimack, US, up and running solutions from December 2021 • Acquisition
Slide 4: Organic order growth in Q4 in all Business Areas and regions
Organic order growth in Q4 In all Business Areas and regions Global Americas EMEA APAC Organic Order Growth +6.4% Organic Net Sales Growth -9.6% Getinge │ Presentation │ Q4 Report 2021 January 28, 2022 Page 4
Slide 5: Outlook 2022
Outlook 2022 Organic net sales growth is expected to be in the upper end of 4-6% for the full year Getinge │ Presentation │ Q4 Report 2021 January 28, 2022 Page 5
Slide 6: Healthy organic order growth in all Business Areas
Healthy organic order growth in all Business Areas Order Intake Bridge Q4 2020 – Q4 2021 Organic change +4.4% +7.0% +9.5% +6.4% 205 72 215 7,629 7,137 MSEK Q4 2020 Acute Care Therapies Life Science Surgical Workflows Q4 2021 Getinge │ Presentation │ Q4 Report 2021 January 28, 2022 Page 6
Slide 7: 29.1% organic Net Sales Growth in Life Science
29.1% organic Net Sales Growth in Life Science Net Sales Bridge Q4 2020 – Q4 2021 Organic change -22.1% +29.1% +4.0% -9.6% MSEK -1,162 237 74 -7 Currency impact, MSEK 7.7 8,839 7,987 Organic growth, % Q4 2020 Acute Care Life Science Surgical Q4 2021 -22.1 Therapies Workflows Capital Consumables Good
Slide 8: Margin improvement in Acute Care Therapies and Surgical Workflows
Margin improvement in Acute Care Therapies and Surgical Workflows Adjusted Gross Profit Bridge Q4 2020 – Q4 2021 Adj GM, % Q4 2021 61.2 39.5 42.4 52.0 (Q4 2020) (59.8) (39.7) (38.4) (51.5) 92 137 Gross Margin impact -635 Volume MSEK 4,556 Business Area mix 4,150 Factory absorption Currency Q4 2020 A
Slide 9: Financial development
Financial development Getinge │ Presentation │ Q4 Report 2021 January 28, 2022 Page 9
Slide 10: Adj EBITA margin improvement
Adj EBITA margin improvement Adjusted EBITA Bridge Q4 2020 – Q4 2021 Margin development -0.1 pp Adj GP 21.6% -1.3 pp Adj OPEX +0.3 pp D&A 20.6% +2.1 pp Currency -94 75 180 92 6 -40 +163 -406 Currency impact, MSEK MSEK 1,817 1,723 Q4 2020 Adj Gross Adj Selling Adj Admin Adj R&D Other D&A Q4 2021 prof
Slide 11: Strong free cash flow and good control of working capital
Strong free cash flow and good control of working capital Continued efficiency enhancements Strong Free Cash Flow WC days well below 100 High Return on Invested Capital 140 Reduction of 40 days 130 from the top 120 110 19.4% 2.3 100 2.0 1.4 90 1.3 1.2 7.5% 80 0 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 202
Slide 12: Solid financial position
Solid financial position Strengthened even further Improved net debt … … and leverage 14.0 3.4x 3.6 (0.2 excluding pension liabilities) 0.5 (0.0 x excluding pension liabilities) Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2019 Q2 2019 Q3 2019 Q4
Slide 13: Summary
Summary Getinge │ Presentation │ Q4 Report 2021 January 28, 2022 Page 13
Slide 14: Key takeaways
Key takeaways Summary Q4 2021 • Good activity level and progress on strategy implementation • Healthy organic order growth • Improved margins • Strong Free Cash Flow • Solid financial position Getinge │ Presentation │ Q4 Report 2021 January 28, 2022 Page 14
Slide 15: Q&A
Q&A Getinge │ Presentation │ Q4 Report 2021 January 28, 2022 Page 15
Slide 16: Thank you
Thank you Getinge │ Presentation │ Q4 Report 2021 January 28, 2022 Page 16
Slide 17: Forward looking information
Forward looking information • This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectati
Slide 18: Getinge – Passion for Life
“= Se A GETINGE PASSION FOR LIFE